Viewing Study NCT01650194

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:00 AM
Ignite Modification Date: 2026-03-05 @ 12:07 AM
Study NCT ID: NCT01650194
Status: COMPLETED
Last Update Posted: 2024-12-10
First Post: 2012-07-24
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
Sponsor: Astellas Pharma Global Development, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Castration-Resistant Prostate Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None abiraterone acetate View
None prednisone View
None enzalutamide View
None cancer View
None prostate View
None MDV3100 View